Adjuvant treatment of postmenopausal women w/ hormone receptor positive invasive early breast cancer. Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 yr. 1st line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Advanced breast cancer after relapse or disease progression, in women w/ natural or artificially-induced postmenopausal endocrine status, who have previously been treated w/ anti-oestrogens. Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable & immediate surgery not indicated.
Only women of postmenopausal endocrine status should receive Femara. Formally assess bone mineral density in women w/ history of osteoporosis &/or fractures or who are at increased risk of osteoporosis, prior to adjuvant & extended adjuvant treatment intiation, & monitor during & following treatment. Rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption. Avoid co-administration w/ tamoxifen, other anti-oestrogens or oestrogen-containing therapies. Minor influence on the ability to drive & use machines. Patients w/ renal impairment (CrCl <10 mL/min) & severe hepatic impairment (Child-Pugh C). May induce ovulation. Not recommended in childn & adolescents.
Possible diminished pharmacological action w/ tamoxifen, other anti-oestrogens or oestrogens-containing therapies. Exercise caution when concomitantly used w/ substrates of CYP450, CYP2A6 or CYP2C19, especially those w/ narrow therapeutic index eg, phenytoin, clopidogrel.
Sign Out
